Press Release

Cinven Completes Majority Investment in BioAgilytix

Investment will Power Further Expansion of Core Business and Drive Future Growth of the Company 

December 21, 2021—Durham, NC, USA and London, UK—BioAgilytix, a leading global contract research organization (CRO), today announced the completion of a majority investment in the Company by Cinven, a leading international private investment firm focused on building world-class global companies.

Cinven’s investment will provide BioAgilytix with increased access to funding and resources to meet the growing demand for its high-quality bioanalytical services, driven by its strong scientific reputation and leading expertise in supporting the development and commercialization of novel therapeutics.

“Today we are pleased to announce the completion of our investment from Cinven. As we start the next chapter of our story, we look forward to this strong partnership that will enable us to fully realize our potential to meet the ever-expanding needs of our customers and the patients they serve,” said Jim Datin, President and CEO of BioAgiltyix. 

“We are excited to partner with Jim and his management and scientific leadership teams, to invest behind the significant additional growth prospects ahead for BioAgilytix ,” said Matthew Norton, Partner at Cinven.

BofA Securities served as lead financial advisor to BioAgilytix, and William Blair and Lazard served as co-advisors. White & Case served as legal advisor and Deloitte LLP as accounting and tax advisor to BioAgilytix.

About BioAgilytix

BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across a number of industries and disease states.

BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit

About Cinven

Cinven is a leading international private equity firm focused on building world-class global companies. Its funds invest in six key sectors: Business Services, Consumer, Financial Services, Healthcare, Industrials and Technology, Media and Telecommunications (TMT). Cinven has offices in London, Frankfurt, Paris, Milan, Madrid, New York, Guernsey and Luxembourg.

Cinven takes a responsible approach towards its portfolio companies, their employees, suppliers, local communities, the environment and society.

Cinven Capital Management (V) General Partner Limited, Cinven Capital Management (VI) General Partner Limited, Cinven Capital Management (VII) General Partner Limited and Cinven Capital Management (SFF) General Partner Limited are each authorised and regulated by the Guernsey Financial Services Commission, and Cinven Limited, the adviser to the Cinven Funds, is authorised and regulated by the Financial Conduct Authority.

In this press release ‘Cinven’ means, depending on the context, any of or collectively, Cinven Holdings Guernsey Limited, Cinven Partnership LLP, Cinven (LuxCo1) S. ὰ.r.l., and their respective Associates (as defined in the Companies Act 2006) and/or funds managed or advised by any of the foregoing.

For additional information on Cinven please visit and

Media Contact:
Kennon Broadhurst

cinven bioagilytix